Constant improvement in surgical treatment and heavy investment in R&D will stimulate the sales of iridocorneal endothelial syndrome
Constant improvement in surgical treatment and heavy investment in R&D will stimulate the sales of iridocorneal endothelial syndrome
Fact.MR, Rockville MD: Award winning market research company Fact.MR is conducting an ongoing research study on the global iridocorneal endothelial syndrome (IES) market. As per its findings, a positive growth outlook is expected for 2021, primarily underpinned by growing cases for glaucoma. Growth prospects for the upcoming decade are also positive, registering an impressive expansion rate until 2029.
According to Fact.MR, the market is poised to benefit immensely from increasing geriatric population. The study evaluates that as there is no direct treatment for IES, demand for treatment, however treatment available for scope such as anti-glaucoma medications and trabeculectomy filtering surgery expected to boost the demand for IES market.
For instance, according to the statistics of World Health Organization, glaucoma is the second leading cause for total blindness and 50% of patients diagnosed with glaucoma suffers from iridocorneal endothelial syndrome. In 2019, 4.5 million people were diagnosed with glaucoma among which 50% of the people were suffering from iridocorneal endothelial syndrome. Hence, bolstering the demand.
“Prominent manufacturers are investing more in research & development activities to find a direct treatment approach and minimal invasive surgeries to improve the accuracy, which helps in removing any severe progressive iris atrophy or chandler syndrome, propelling the growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3988
Key Takeaways
- Absorbable Iridocorneal Endothelial Syndrome are expected to garner significant traction in the forthcoming years
- US to be the epicenter of iridocorneal endothelial syndrome, owing to the healthcare expenditure
- Australia and New Zealand to emerge as a potential market through 2021
- Favorable government initiatives and advancement in healthcare infrastructure to spur IES sales across France and UK
- Surging cases of iridocorneal endothelial syndrome in India prevailing the sales
- On the basis of treatment, anti-glaucoma medications and trabeculectomy filtering surgery expected to be lucrative segments
Prominent Drivers
- Rising geriatric population is the key factor for surging cases of iridocorneal endothelial syndrome market
- Increasing demand for glaucoma treatment to proliferate iridocorneal endothelial syndrome sales
Key Restraints
- Major side effects such as high blood pressure and irregular heart rate for anti-glaucoma medication to pose a challenge for IES market
- Unpredictability of patients postoperative intraocular pressure for trabeculectomy filtering surgery to hamper the sales
Discover more about the Iridocorneal Endothelial Syndrome market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3988/iridocorneal-endothelial-syndrome-market
Competitive Landscape
Key Iridocorneal Endothelial Syndrome market players profiled by Fact.MR include Sun Pharmaceutical Industries Ltd., Cipla, Lupin Ltd., Allergan PLC., Micro Labs Ltd., and Ajanta Pharma Ltd. among others. Researchers and manufacturers are investing heavily in R&D for new treatment and minimal invasive surgeries for the IES treatment.
In 2020, Harvard eye associates developed a new drug called Durysta, which was the only treatment approved by FDA for glaucoma patients which helped them with IES syndrome.
Also, in December 2020, researchers found a possible non-drug treatment that uses the injection of a natural and biodegradable material to create a hydrogel that will treat the patient with IES and reduce the treatment with injection.
More Insights on the Iridocorneal Endothelial Syndrome Market
A recent study by Fact.MR offers an exhaustive analysis on the global iridocorneal endothelial syndrome market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of treatment (anti-glaucoma medications, trabeculectomy filtering surgery, seton or valve surgery, and cyclodestruction), type (chandler syndrome, essential/progressive iris atrophy, iris nevus/cogan-reese syndrome), end-user (hospitals, ambulatory surgical centers, and specialty clinics), and regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa)
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=3988
Explore Fact.MR’s Coverage on the Healthcare Domain
Glaucoma Diagnostics Market: A recent study by Fact.MR on the glaucoma diagnostics market offers an unbiased analysis on the opportunities and challenges for the forecast period. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players.
Corneal Transplantation Surgical Instrument Package Market: A detailed assessment of corneal transplantation surgical instrument package value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Eye Socket Implants Market: Fact.MR has published an incisive coverage on the global market for eye socket implants market. A comprehensive estimate on eye socket implant market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the detailed segmentation and exhaustive competitive landscape during the forecast period.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR